To sustained release of an anticancer drug, oxaliplatin (OX), a non-toxic and biocompatible nanocarrier based on bovine serum albumin (BSA) were synthesised by desolvation method and characterised using Fourier-transform infrared (FTIR) spectroscopy, field emission scanning electron microscopy (FESEM), atomic force microscopy (AFM) and dynamic light scattering. The results showed that the BSA nanoparticles (BSANPs) with a mean magnitude of 187.9 ± 1.2 nm have spherical morphology with a smooth surface and a uniform distribution. Furthermore, OX was loaded onto the BSANPs and the loading was confirmed by FTIR, AFM and FESEM techniques. The percentage of encapsulation efficiency and drug loading were determined by absorption spectroscopy (UV-vis). The drug release studies showed that release of OX from BSANPs exhibited slower release rate. However, the release kinetics followed the first-order kinetic for both of them with the non-Fickian release behaviour. The electrochemical analysis showed stability of OX loaded onto the BSANPs (OX@BSANPs) and confirmed the diffusion mechanism. Furthermore, the results of MTT assay revealed increasing of normal cell viability and cancer cell death in the OX@BSANPs compared to only OX. It was shown that the BSANPs could be safely used as a biocompatible nanocarrier for the sustained release of OX.

中文翻译：

---

使用牛血清白蛋白纳米颗粒提高奥沙利铂抗癌药物的疗效和降低细胞毒性：合成、表征和释放行为。

为了缓释抗癌药物，奥沙利铂（OX）是一种基于牛血清白蛋白（BSA）的无毒生物相容性纳米载体，采用去溶剂法合成，并使用傅里叶变换红外（FTIR）光谱、场发射扫描电子显微镜对其进行表征。 (FESEM)、原子力显微镜 (AFM) 和动态光散射。结果表明，平均大小为 187.9 ± 1.2 nm 的 BSA 纳米颗粒 (BSNPs) 具有球形形态，表面光滑，分布均匀。此外，将 OX 加载到 BSNP 上，并通过 FTIR、AFM 和 FESEM 技术确认加载。通过吸收光谱（UV-vis）测定包封效率和载药量的百分比。药物释放研究表明，从 BSANPs 释放 OX 的释放速度较慢。然而，释放动力学遵循它们的一级动力学，具有非 Fickian 释放行为。电化学分析表明 OX 负载在 BSANPs (OX@BSANPs) 上的稳定性并证实了扩散机制。此外，MTT 测定的结果显示，与仅 OX 相比，OX@BSANPs 中的正常细胞活力和癌细胞死亡增加。结果表明，BSANPs可以安全地用作OX缓释的生物相容性纳米载体。MTT 测定的结果显示，与仅 OX 相比，OX@BSANPs 中的正常细胞活力和癌细胞死亡增加。结果表明，BSANPs可以安全地用作OX缓释的生物相容性纳米载体。MTT 测定的结果显示，与仅 OX 相比，OX@BSANPs 中的正常细胞活力和癌细胞死亡增加。结果表明，BSANPs可以安全地用作OX缓释的生物相容性纳米载体。